D
Coherus BioSciences, Inc.
CHRS
$0.8306
-$0.0797-8.76%
D
Sell
3/18/2025Upgraded
Coherus BioSciences, Inc. (CHRS) was upgraded to D from E+ on 3/18/2025 due to a significant increase in the valuation index, efficiency index and growth index. Operating cash flow increased 146.13% from -$62.02M to $28.61M.
Coherus BioSciences, Inc. (CHRS) was upgraded to D from E+ on 3/18/2025 due to a significant increase in the valuation index, efficiency index and growth index. Operating cash flow increased 146.13% from -$62.02M to $28.61M.
E
Sell
7/14/2023Downgrade
Coherus BioSciences, Inc. (CHRS) was downgraded to E+ from D- on 7/14/2023 due to a major decline in the growth index, total return index and volatility index. Total revenue declined 28.48% from $45.35M to $32.44M, and earnings per share declined from -$0.761 to -$0.9553.
Coherus BioSciences, Inc. (CHRS) was downgraded to E+ from D- on 7/14/2023 due to a major decline in the growth index, total return index and volatility index. Total revenue declined 28.48% from $45.35M to $32.44M, and earnings per share declined from -$0.761 to -$0.9553.
D
Sell
3/22/2023Downgrade
Coherus Biosciences, Inc. (CHRS) was downgraded to D- from D on 3/22/2023 due to a decline in the volatility index and total return index.
Coherus Biosciences, Inc. (CHRS) was downgraded to D- from D on 3/22/2023 due to a decline in the volatility index and total return index.
D
Sell
3/7/2023Upgraded
Coherus Biosciences, Inc. (CHRS) was upgraded to D from D- on 3/7/2023 due to a major increase in the growth index and volatility index. Earnings per share increased from -$1.1145 to -$0.761.
Coherus Biosciences, Inc. (CHRS) was upgraded to D from D- on 3/7/2023 due to a major increase in the growth index and volatility index. Earnings per share increased from -$1.1145 to -$0.761.
D
Sell
11/10/2022Downgrade
Coherus Biosciences, Inc. (CHRS) was downgraded to D- from D on 11/10/2022 due to a noticeable decline in the growth index. Earnings per share declined from -$0.6466 to -$1.1145, total revenue declined 24.48% from $60.15M to $45.42M, and EBIT declined 23.71% from -$44.01M to -$54.45M.
Coherus Biosciences, Inc. (CHRS) was downgraded to D- from D on 11/10/2022 due to a noticeable decline in the growth index. Earnings per share declined from -$0.6466 to -$1.1145, total revenue declined 24.48% from $60.15M to $45.42M, and EBIT declined 23.71% from -$44.01M to -$54.45M.
D
Sell
9/23/2022Upgraded
Coherus Biosciences, Inc. (CHRS) was upgraded to D from D- on 9/23/2022 due to an increase in the total return index and volatility index.
Coherus Biosciences, Inc. (CHRS) was upgraded to D from D- on 9/23/2022 due to an increase in the total return index and volatility index.
D
Sell
8/8/2022Upgraded
Coherus Biosciences, Inc. (CHRS) was upgraded to D- from E+ on 8/8/2022 due to a noticeable increase in the growth index and valuation index. Earnings per share increased from -$1.2437 to -$0.6466, EBIT increased 45.61% from -$80.93M to -$44.01M, and operating cash flow increased 7.42% from -$54.05M to -$50.04M.
Coherus Biosciences, Inc. (CHRS) was upgraded to D- from E+ on 8/8/2022 due to a noticeable increase in the growth index and valuation index. Earnings per share increased from -$1.2437 to -$0.6466, EBIT increased 45.61% from -$80.93M to -$44.01M, and operating cash flow increased 7.42% from -$54.05M to -$50.04M.
E
Sell
5/6/2022Downgrade
Coherus Biosciences, Inc. (CHRS) was downgraded to E+ from D- on 5/6/2022 due to a noticeable decline in the solvency index, total return index and volatility index. Debt to equity increased from 4.21 to 33.74, and the quick ratio declined from 3.27 to 2.88.
Coherus Biosciences, Inc. (CHRS) was downgraded to E+ from D- on 5/6/2022 due to a noticeable decline in the solvency index, total return index and volatility index. Debt to equity increased from 4.21 to 33.74, and the quick ratio declined from 3.27 to 2.88.
D
Sell
3/4/2022Downgrade
Coherus Biosciences, Inc. (CHRS) was downgraded to D- from D on 3/4/2022 due to a decline in the solvency index, efficiency index and growth index. Operating cash flow declined 481.61% from $13.71M to -$52.32M, EBIT declined 73.48% from -$27.59M to -$47.86M, and debt to equity increased from 3.14 to 4.21.
Coherus Biosciences, Inc. (CHRS) was downgraded to D- from D on 3/4/2022 due to a decline in the solvency index, efficiency index and growth index. Operating cash flow declined 481.61% from $13.71M to -$52.32M, EBIT declined 73.48% from -$27.59M to -$47.86M, and debt to equity increased from 3.14 to 4.21.
D
Sell
8/30/2021Upgraded
Coherus Biosciences, Inc. (CHRS) was upgraded to D from D- on 8/30/2021 due to an increase in the volatility index and total return index.
Coherus Biosciences, Inc. (CHRS) was upgraded to D from D- on 8/30/2021 due to an increase in the volatility index and total return index.
D
Sell
8/6/2021Downgrade
Coherus Biosciences, Inc. (CHRS) was downgraded to D- from D on 8/6/2021 due to a noticeable decline in the total return index, growth index and volatility index. Operating cash flow declined 113.75% from $1.37M to -$188.
Coherus Biosciences, Inc. (CHRS) was downgraded to D- from D on 8/6/2021 due to a noticeable decline in the total return index, growth index and volatility index. Operating cash flow declined 113.75% from $1.37M to -$188.
D
Sell
5/10/2021Downgrade
Coherus Biosciences, Inc. (CHRS) was downgraded to D from C on 5/10/2021 due to a significant decline in the valuation index, efficiency index and growth index. Earnings per share declined from $0.1241 to -$2.3746, net income declined 1,881.49% from $9.71M to -$172.95M, and EBIT declined 1,099.39% from $16.43M to -$164.15M.
Coherus Biosciences, Inc. (CHRS) was downgraded to D from C on 5/10/2021 due to a significant decline in the valuation index, efficiency index and growth index. Earnings per share declined from $0.1241 to -$2.3746, net income declined 1,881.49% from $9.71M to -$172.95M, and EBIT declined 1,099.39% from $16.43M to -$164.15M.
C
Hold
3/3/2021Upgraded
Coherus Biosciences, Inc. (CHRS) was upgraded to C from C- on 3/3/2021 due to a significant increase in the efficiency index, volatility index and valuation index. Total capital increased 3.8% from $672.55M to $698.08M.
Coherus Biosciences, Inc. (CHRS) was upgraded to C from C- on 3/3/2021 due to a significant increase in the efficiency index, volatility index and valuation index. Total capital increased 3.8% from $672.55M to $698.08M.
C
Hold
8/7/2020Downgrade
Coherus Biosciences, Inc. (CHRS) was downgraded to C- from C on 8/7/2020 due to a significant decline in the efficiency index and total return index.
Coherus Biosciences, Inc. (CHRS) was downgraded to C- from C on 8/7/2020 due to a significant decline in the efficiency index and total return index.
C
Hold
2/28/2020Upgraded
Coherus Biosciences, Inc. (CHRS) was upgraded to C from D on 2/28/2020 due to a significant increase in the valuation index, efficiency index and solvency index. Debt to equity declined from 3.21 to 1.72, and total capital increased 20.02% from $246.67M to $296.05M.
Coherus Biosciences, Inc. (CHRS) was upgraded to C from D on 2/28/2020 due to a significant increase in the valuation index, efficiency index and solvency index. Debt to equity declined from 3.21 to 1.72, and total capital increased 20.02% from $246.67M to $296.05M.
D
Sell
11/12/2019Upgraded
Coherus Biosciences, Inc. (CHRS) was upgraded to D from D- on 11/12/2019 due to a substantial increase in the growth index, efficiency index and total return index. Operating cash flow increased 333.47% from $12.68M to $54.95M, net income increased 99.61% from $23.57M to $47.04M, and earnings per share increased from $0.32 to $0.6304.
Coherus Biosciences, Inc. (CHRS) was upgraded to D from D- on 11/12/2019 due to a substantial increase in the growth index, efficiency index and total return index. Operating cash flow increased 333.47% from $12.68M to $54.95M, net income increased 99.61% from $23.57M to $47.04M, and earnings per share increased from $0.32 to $0.6304.
D
Sell
8/9/2018Downgrade
Coherus Biosciences, Inc. (CHRS) was downgraded to D- from D on 8/9/2018 due to a decline in the efficiency index, valuation index and growth index. EBIT declined 6.85% from -$42.03M to -$44.91M, and operating cash flow declined 5.79% from -$33.58M to -$35.53M.
Coherus Biosciences, Inc. (CHRS) was downgraded to D- from D on 8/9/2018 due to a decline in the efficiency index, valuation index and growth index. EBIT declined 6.85% from -$42.03M to -$44.91M, and operating cash flow declined 5.79% from -$33.58M to -$35.53M.
D
Sell
5/11/2018Upgraded
Coherus Biosciences, Inc. (CHRS) was upgraded to D from D- on 5/11/2018 due to an increase in the valuation index, solvency index and total return index. Debt to equity declined from 3.19 to -56.84.
Coherus Biosciences, Inc. (CHRS) was upgraded to D from D- on 5/11/2018 due to an increase in the valuation index, solvency index and total return index. Debt to equity declined from 3.19 to -56.84.
D
Sell
3/12/2018Upgraded
Coherus Biosciences, Inc. (CHRS) was upgraded to D- from E+ on 3/12/2018 due to a large increase in the growth index and efficiency index. Operating cash flow increased 27.92% from -$41.51M to -$29.92M, earnings per share increased from -$1.091 to -$0.841, and net income increased 16.82% from -$58.99M to -$49.07M.
Coherus Biosciences, Inc. (CHRS) was upgraded to D- from E+ on 3/12/2018 due to a large increase in the growth index and efficiency index. Operating cash flow increased 27.92% from -$41.51M to -$29.92M, earnings per share increased from -$1.091 to -$0.841, and net income increased 16.82% from -$58.99M to -$49.07M.
E
Sell
12/1/2017Downgrade
Coherus Biosciences, Inc. (CHRS) was downgraded to E+ from D- on 12/1/2017 due to a substantial decline in the growth index, total return index and volatility index. EBIT declined 6.74% from -$53.04M to -$56.62M, and earnings per share declined from -$1.0788 to -$1.091.
Coherus Biosciences, Inc. (CHRS) was downgraded to E+ from D- on 12/1/2017 due to a substantial decline in the growth index, total return index and volatility index. EBIT declined 6.74% from -$53.04M to -$56.62M, and earnings per share declined from -$1.0788 to -$1.091.
D
Sell
8/9/2017Downgrade
Coherus Biosciences, Inc. (CHRS) was downgraded to D- from D on 8/9/2017 due to a large decline in the solvency index, total return index and volatility index. Debt to equity increased from 1.29 to 3.14, and the quick ratio declined from 3.7 to 3.29.
Coherus Biosciences, Inc. (CHRS) was downgraded to D- from D on 8/9/2017 due to a large decline in the solvency index, total return index and volatility index. Debt to equity increased from 1.29 to 3.14, and the quick ratio declined from 3.7 to 3.29.
D
Sell
3/15/2017Downgrade
Coherus Biosciences, Inc. (CHRS) was downgraded to D from D+ on 3/15/2017 due to a decline in the valuation index.
Coherus Biosciences, Inc. (CHRS) was downgraded to D from D+ on 3/15/2017 due to a decline in the valuation index.
D
Sell
8/30/2016Upgraded
Coherus Biosciences, Inc. (CHRS) was upgraded to D+ from D on 8/30/2016 due to an increase in the valuation index.
Coherus Biosciences, Inc. (CHRS) was upgraded to D+ from D on 8/30/2016 due to an increase in the valuation index.
D
Sell
12/9/2015Downgrade
Coherus Biosciences, Inc. (CHRS) was downgraded to D from D+ on 12/9/2015 due to a decline in the volatility index.
Coherus Biosciences, Inc. (CHRS) was downgraded to D from D+ on 12/9/2015 due to a decline in the volatility index.
D
Sell
11/13/2015Upgraded
Coherus Biosciences, Inc. (CHRS) was upgraded to D+ from D on 11/13/2015 due to an increase in the growth index. Operating cash flow increased 186.25% from -$20.84M to -$59.66M, EBIT increased 20.92% from -$58.9M to -$71.22M, and earnings per share increased from -$1.5611 to -$1.8564.
Coherus Biosciences, Inc. (CHRS) was upgraded to D+ from D on 11/13/2015 due to an increase in the growth index. Operating cash flow increased 186.25% from -$20.84M to -$59.66M, EBIT increased 20.92% from -$58.9M to -$71.22M, and earnings per share increased from -$1.5611 to -$1.8564.
D
Sell
10/28/2015Upgraded
Coherus BioSciences, Inc. (CHRS) was upgraded to D from D- on 10/28/2015.
Coherus BioSciences, Inc. (CHRS) was upgraded to D from D- on 10/28/2015.
D
Sell
10/8/2015Downgrade
Coherus Biosciences, Inc. (CHRS) was downgraded to D- from D on 10/8/2015 due to a decline in the volatility index.
Coherus Biosciences, Inc. (CHRS) was downgraded to D- from D on 10/8/2015 due to a decline in the volatility index.
D
Sell
9/23/2015Upgraded
Coherus Biosciences, Inc. (CHRS) was upgraded to D from D- on 9/23/2015 due to an increase in the volatility index.
Coherus Biosciences, Inc. (CHRS) was upgraded to D from D- on 9/23/2015 due to an increase in the volatility index.
D
Sell
9/8/2015Downgrade
Coherus Biosciences, Inc. (CHRS) was downgraded to D- from D on 9/8/2015 due to a decline in the growth index. Operating cash flow declined 36.97% from -$33.06M to -$20.84M.
Coherus Biosciences, Inc. (CHRS) was downgraded to D- from D on 9/8/2015 due to a decline in the growth index. Operating cash flow declined 36.97% from -$33.06M to -$20.84M.
D
Sell
6/8/2015Upgraded
Coherus Biosciences, Inc. (CHRS) was upgraded to D from E+ on 6/8/2015 due to an increase in the growth index. EBIT increased 38.36% from -$26.56M to -$36.75M.
Coherus Biosciences, Inc. (CHRS) was upgraded to D from E+ on 6/8/2015 due to an increase in the growth index. EBIT increased 38.36% from -$26.56M to -$36.75M.
E
Sell
5/1/2015Upgraded
Coherus Biosciences, Inc. (CHRS) was upgraded to E+ from E on 5/1/2015 due to an increase in the valuation index.
Coherus Biosciences, Inc. (CHRS) was upgraded to E+ from E on 5/1/2015 due to an increase in the valuation index.
E
Sell
4/16/2015Downgrade
Coherus Biosciences, Inc. (CHRS) was downgraded to E from D on 4/16/2015 due to a decline in the total return index.
Coherus Biosciences, Inc. (CHRS) was downgraded to E from D on 4/16/2015 due to a decline in the total return index.
D
Sell
4/14/2015Upgraded
Coherus BioSciences, Inc. (CHRS) was upgraded to D from E on 04/14/2015.
Coherus BioSciences, Inc. (CHRS) was upgraded to D from E on 04/14/2015.
E
Sell
4/10/2015Downgrade
Coherus Biosciences, Inc. (CHRS) was downgraded to E from D on 4/10/2015 due to a decline in the total return index.
Coherus Biosciences, Inc. (CHRS) was downgraded to E from D on 4/10/2015 due to a decline in the total return index.
D
Sell
3/31/2015Upgraded
Coherus Biosciences, Inc. (CHRS) was upgraded to D from E on 3/31/2015 due to a noticeable increase in the solvency index and volatility index. The quick ratio increased from 2.1 to 2.95.
Coherus Biosciences, Inc. (CHRS) was upgraded to D from E on 3/31/2015 due to a noticeable increase in the solvency index and volatility index. The quick ratio increased from 2.1 to 2.95.
E
Sell
3/19/2015Downgrade
Coherus Biosciences, Inc. (CHRS) was downgraded to E from C- on 3/19/2015 due to a decline in the volatility index and total return index.
Coherus Biosciences, Inc. (CHRS) was downgraded to E from C- on 3/19/2015 due to a decline in the volatility index and total return index.
C
Hold
3/17/2015Upgraded
Coherus Biosciences, Inc. (CHRS) was upgraded to C- from E on 3/17/2015 due to an increase in the total return index and volatility index.
Coherus Biosciences, Inc. (CHRS) was upgraded to C- from E on 3/17/2015 due to an increase in the total return index and volatility index.
E
Sell
3/5/2015Downgrade
Coherus BioSciences, Inc. (CHRS) was downgraded to E from C- on 03/05/2015.
Coherus BioSciences, Inc. (CHRS) was downgraded to E from C- on 03/05/2015.
C
Hold
2/25/2015Upgraded
Coherus Biosciences, Inc. (CHRS) was upgraded to C- from E on 2/25/2015 due to an increase in the total return index and volatility index.
Coherus Biosciences, Inc. (CHRS) was upgraded to C- from E on 2/25/2015 due to an increase in the total return index and volatility index.
E
Sell
2/10/2015Downgrade
Coherus Biosciences, Inc. (CHRS) was downgraded to E from C- on 2/10/2015 due to a decline in the total return index.
Coherus Biosciences, Inc. (CHRS) was downgraded to E from C- on 2/10/2015 due to a decline in the total return index.
C
Hold
2/9/2015Upgraded
Coherus Biosciences, Inc. (CHRS) was upgraded to C- from E on 2/9/2015 due to a significant increase in the total return index and volatility index.
Coherus Biosciences, Inc. (CHRS) was upgraded to C- from E on 2/9/2015 due to a significant increase in the total return index and volatility index.
E
Sell
2/3/2015None
Coherus BioSciences, Inc. (CHRS) was downgraded to E from U on 02/03/2015.
Coherus BioSciences, Inc. (CHRS) was downgraded to E from U on 02/03/2015.
NASDAQ
04/03/2025 1:37PM Eastern
Quotes delayed
